January 24, 2013 — Results of clinical research that treated mesothelioma with radiation before surgery show the three-year survival rate more than doubled for study participants afflicted with this deadly disease, compared to treating with surgery first.
 
The Journal of Thoracic Oncology published the findings, which chart a route to treat patients effectively and improve their quality of life and potential survival, said principal investigator and lead author John Cho, M.D., radiation oncologist at Princess Margaret Cancer Centre, University Health Network (UHN). 
 
“The patients in our study experienced shorter treatment, fewer complications and speedier recovery,” Dr. Cho said. “The three-year survival rate more than doubled to 72 percent from 32 percent.” 
 
Mesothelioma is an aggressive malignancy that starts in the lining of the lung and progressively restricts and invades the whole organ. The study assessed Surgery for Mesothelioma After Radiation Therapy (SMART), which was completed over four years with 25 patients who underwent radiation therapy at Princess Margaret Cancer Centre and surgery at Toronto General Hospital, both part of UHN.
 
Participants were treated with an accelerated, five-day course of intensity-modulated radiation therapy (IMRT), a specialized technique that conforms the radiation dose around the tumors in 3-D while sparing the heart, spine and other healthy tissues. Patients’ affected lungs were removed the following week. 
 
The SMART approach reduced the treatment cycle for patients to one month from five months and reduced the risk of recurrence because radiation prevented the cancer from seeding elsewhere in the chest or abdomen during surgery.
 
Exposure to asbestos is the main cause of mesothelioma in the 500 new cases reported in Canada each year.
 
For more information: www.theprincessmargaret.ca, www.uhn.ca

Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Artificial Intelligence

June 11, 2024 — A new study led by researchers at Emory AI.Health, published in the Journal of Computers in Medicine and ...

Time June 11, 2024
arrow
Subscribe Now